Kevin Mulleady Discusses New Advancements in the Medical Industry

Kevin Mulleady’s newest undertaking is Altru-Sciences, a biopharmaceutical company focusing on patients with unmet needs. Throughout his career, Mulleady has seen the medical industry advance and observed how these changes have affected patients from all over the world. His interest has not only helped him forge a new path in the market but it’s also brought new opportunities along with it. He shares his insights about the past in an effort to understand both the present and the future better.

What’s New and Now

The medical industry has gone through a lot of turmoil over the past few decades. Pharmaceuticals, technology, research, biology, and chemistry are just a few fields that require convergence in order to improve patient care. This was a merging of the minds in some respects, but it caused a good deal of conflict too.

Mulleady of Altru-Sciences may have earned his degree in Mechanical & Aerospace Engineering, but he’s kept a close eye on the fluctuations of the healthcare sector. What he saw was certainly a lot of controversy, but there was a lot of potential as well. This double-sided coin inspired him to become a founder and co-founder in a variety of businesses that would ultimately support patients without a lot of options for care.

Unmet Patient Needs

There’s a degree of disconnect in healthcare that has made advancements difficult for healthcare professionals, and it all begins with what the sector chooses to focus on. Certain causes and conditions are well known in the public eye. From diabetes to breast cancer, these disorders get the funding and attention they need to improve treatment options.

Mulleady has tracked how the publicity results in action and what that has meant for patients who desperately need the results. For decades, some people were met with cutting-edge treatments that pushed the boundaries of science. Others were met with little more than guesses and a hope for the best. They were left to struggle on their own or seek out alternative treatments.

In more recent years, though, Kevin Mulleady of Altru-Sciences has started to see a change in how different kinds of patients are addressed. He’s starting to see more startups emerge that address the less ‘popular’ conditions that have been largely avoided. These startups rely on everything from the latest studies to smartphone technology to provide more sustainable solutions.

This reimagining of how patients are treated is where Mulleady’s passion lies. He looks for treatment options that treat rare or otherwise ignored issues. This is a way to even the playing field for everyone, ensuring that more people get access to the medications, devices, and procedures that will ultimately help them defeat (or at least manage) their condition.

Finding a Balance

Despite the many advancements in patient care today, treatment remains largely uneven. Doctors and other healthcare professionals operate under various circumstances, based on everything from their initial training to organizational constraints.

Ultimately, this has meant that different people can approach the same problem with wildly different approaches — some of which are more effective than others. Kevin Mulleady didn’t want to see the advancements go to people who already had access to the best possible care.

What he wanted to see was a better sense of balance. From the patents under his portfolio umbrella to the funding of rare children’s diseases research out of his own pocket, his mission was to be a part of the latest developments and ensure they went into the hands of people who needed them the most.

Mulleady has been involved in a number of ventures, including consulting, biotech, and fintech. His whole career has been about keeping up with evolving markets and then analyzing them to see where and how they fit into the lives of people from every background. As Altru-Sciences moves forward, he’ll continue to find ways to push the boundaries, particularly for those patients who don’t always get the kind of publicity they deserve.